Your browser doesn't support javascript.
loading
Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission.
Shadman, Mazyar; Pasquini, Marcelo; Ahn, Kwang Woo; Chen, Yue; Turtle, Cameron J; Hematti, Peiman; Cohen, Jonathon B; Khimani, Farhad; Ganguly, Siddhartha; Merryman, Reid W; Yared, Jean A; Locke, Frederick L; Ahmed, Nausheen; Munshi, Pashna N; Beitinjaneh, Amer; Reagan, Patrick M; Herrera, Alex F; Sauter, Craig S; Kharfan-Dabaja, Mohamed A; Hamadani, Mehdi.
Afiliación
  • Shadman M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Pasquini M; Division of Medical Oncology, University of Washington, Seattle, WA.
  • Ahn KW; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
  • Chen Y; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
  • Turtle CJ; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI.
  • Hematti P; Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.
  • Cohen JB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
  • Khimani F; Division of Medical Oncology, University of Washington, Seattle, WA.
  • Ganguly S; Division of Hematology, Oncology and Bone Marrow Transplantation, Department of Medicine, University of Wisconsin, Madison, WI.
  • Merryman RW; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.
  • Yared JA; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Locke FL; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
  • Ahmed N; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA.
  • Munshi PN; Blood & Marrow Transplantation Program, Division of Hematology/Oncology, Department of Medicine, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD.
  • Beitinjaneh A; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
  • Reagan PM; Division of Hematological Malignancy and Cellular Therapeutics, University of Kansas Health System, Kansas City, KS.
  • Herrera AF; Stem Cell Transplant and Cellular Immunotherapy Program, MedStar Georgetown University Hospital, Washington, DC.
  • Sauter CS; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL.
  • Kharfan-Dabaja MA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
  • Hamadani M; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Blood ; 139(9): 1330-1339, 2022 03 03.
Article en En | MEDLINE | ID: mdl-34570879
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Linfoma de Células B Grandes Difuso / Trasplante de Células Madre Hematopoyéticas Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Blood Año: 2022 Tipo del documento: Article